Singapore markets open in 27 minutes
Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
64,447.41 -2,068.64 (-3.11%) CMC Crypto 200
1,389.93 -34.17 (-2.40%)
Gilead Sciences Inc (GIS.HA)
Hanover - Hanover Delayed price. Currency in EUR
Add to watchlist
At close: 08:03AM CEST
| Previous close | 62.69 |
| Open | 62.50 |
| Bid | 62.65 x 0 |
| Ask | 62.72 x 0 |
| Day's range | 62.50 - 62.50 |
| 52-week range | 61.81 - 80.14 |
| Volume | |
| Avg. volume | 8 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWhat's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
© 2024 Yahoo. All rights reserved.